image

Key updates

What's new on Wikilite
Section Contents
  • What's new on Wikilite
    • Key updates


Date Publication Update
23/11/2018
Tan 2018 [1210]Section 25.9. Management of multiple myeloma in Asia: resource-stratified guidelines
23/11/2018
ASH abstracts

Section 14.2. Monoclonal sFLCs and SMM progression
Section 14.4. The prognostic value of changes in monoclonal protein concentration
Section 18.3.4. Early detection of disease relapse
Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 24.4. Urine compliance
Section 28.1 AL amyloidosis introduction
Section 28.2.1 Localised amyloid disease
Section 28.8. Prognostic value of sFLC response
Section 32.3.3. sFLC and WM prognosis
Section 33.4. Prognostic value of combined FLC measurements
21/11/2018
Quock 2018 [1197]Section 28.1. Introduction to AL amyloidosis
16/11/2018
Kourelis 2018 [1196]Section 28.1. Introduction to AL amyloidosis
Jabor 2018 [1195]
Section 7.2.6 Freelite biological variation
Section 11.2.6 Hevylite biological variation
15/11/2018
Heaney 2018 [1192]Section 20.1. Introduction to multiple myeloma prognosis
Kastritis 2014 [1193]Section 20.1. Introduction to multiple myeloma prognosis
Sorrig 2017 [1194]Section 20.1. Introduction to multiple myeloma prognosis
14/11/2018
Yadav 2018 [1191]Section 15.1. Diagnosis of light chain multiple myeloma
Section 17.2. Free light chains at diagnosis
Section 20.1. Multiple myeloma prognosis: Introduction
Section 26.4. Nephrotoxicity of monoclonal FLCs
*NEW* Figure 26.2. Higher sFLC levels are associated with more severe renal impairment.
Section 27.1. Renal impairment in multiple myeloma
08/11/2018
Qiu 2018 [1189]Section 28.5.2. Patients with low amyloidogenic FLCs
Nguyen 2018 [1190]Section 28.5.2. Patients with low amyloidogenic FLCs
07/11/2018
Gavriatopoulou 2018 [1188]Section 29.2. sFLC assays support a diagnosis of LCDD
Section 29.3. Monitoring LCDD using sFLC assays
Section 34.4. POEMS syndrome
06/11/2018
Kyle 2018 [1016]Section 32.1. Introduction to Waldenström's macroglobulinaemia
Kyle 2012 [996]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
Pophali 2018 [1185]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
Alexanian 2003 [1186]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
Kyle 2016 [1187]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
29/10/2018
Jacobs 2018 [1178]
*NEW* Section 8.4.5. Sample redilution
Section 8.6.1. Comparison of absolute values
Section 8.6.4. Monitoring MM
Lutteri 2018 [1179]
Section 8.5.2. Renal reference interval
Caponi 2018 [1184]
Section 8.6.1. Comparison of absolute values
Lutteri 2018 [1181]
Section 8.5.2. Renal reference interval
Tate 2018 [1182]
Section 8.5.2. Renal reference interval
18/10/2018
Esplin 2013 [1167]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Lee 2013 [1168]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Palladini 2018 [1169]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Lim 2018 [1170]*NEW* Chapter 28.5.1. Cardiac amyloidosis
National Amyloidosis Centre. Amyloidosis FAQ [1177]
*NEW* Chapter 28.5.1. Cardiac amyloidosis
Muchtar 2017 [1171]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Siddiqi 2017 [1172]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Gertz 2015 [1173]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Gertz 2018 [1174]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Geller 2017 [1175]*NEW* Chapter 28.5.1. Cardiac amyloidosis
Fajardo 2018 [1176]
*NEW* Chapter 28.5.1. Cardiac amyloidosis
17/10/2018
Kumar 2018 [1162]
Section 28.1 Introduction to AL amyloidosis
17/10/2018
Scott 2018 [1166]
Section 20.1. Introduction to multiple myeloma prognosis
17/10/2018
Radocha 2018 [1165]
Section 20.1. Introduction to multiple myeloma prognosis
17/10/2018
Avet-Loiseau 2013 [1164]
Section 20.1. Introduction to multiple myeloma prognosis
17/10/2018
Chng 2014 [1163]
Section 20.1. Introduction to multiple myeloma prognosis
10/10/2018
Jamil 2018 [1160]
Section 37.2.2. Freelite and Hevylite Precision on the Optilite
10/10/2018
Caillon 2018 [1159]

Section 15.2. Monitoring light chain multiple myeloma
Section 24.8. Comparison of sFLCs and urinalysis for monitoring patients
10/10/2018
Rassner 2018 [1158]
Section 7.5.2. Instruments without automated antigen excess checking
10/10/2018
Aberer 2018 [1157]
Section 35.5. Diabetes mellitus
04/10/2018
Dispenzieri 2018 [1156]
Section 34.4. POEMS syndrome
03/10/2018
Arkir 2011 [1153]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Benard 2016 [1148]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Cha 2014 [1154]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Jacobs 2018 [1065]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Laurent 2015 [1149]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
LeSourd 2009 [1150]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Ludwig 2008 [1155]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Leung 2017 [1146]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Marionneaux 2008 [1147]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
McEntee 2016 [1145]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Mirbahai 2011 [1152]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Stone 2018 [1143]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Thouless 2015 [1144]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
Uner 2017 [1151]
*NEW* Chapter 37. Freelite and Hevylite immunoassay instrumentation
27/09/2018
Higgins 2018 [1138]
26.4. Nephrotoxicity of monoclonal FLCs
27/09/2018
Corre 2018 [1140]

19.1. Introduction
19.2. Clonal populations in MM
19.3. Clonal changes and clonal escape in MM
27/09/2018
Tang 2018 [1139]
18.3.5. Monitoring patients treated with mAb-based therapies
27/09/2018
Verstappen 2018 [1142]
Section 35.4.2. Primary Sjögren’s syndrome
26/09/2018
Varga 2018 [1141]
*NEW* Section 36.4. Other applications of CSF FLC measurements
24/09/2018
Kumar 2018 [1129]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Owen 2003 [1128]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Swerdlow 2017 [1127]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Buske 2018 [1126]
Section 32.1. Introduction to Waldenström's macroglobulinaemia
24/09/2018
Kastritis 2018 [1125]

Section 32.1. Introduction to Waldenström's macroglobulinaemia
Section 32.2. IgM quantitation by routine laboratory tests
*NEW* Section 32.3.4. Guidelines for sFLC assessment in WM
20/09/2018
AACC 2018 abstracts

Section 13.1. MGUS definition and frequency
Section 23.3. Incorporation of sFLC analysis into routine screening for monoclonal gammopathies
Section 35.4.1. Systemic lupus erythematosus
20/09/2018
ISA 2018 abstracts

Section 28.1. Introduction to AL amyloidosis
Section 28.4. Prognostic value of sFLCs at diagnosis
Section 28.8.1. sFLC response predicting cardiac outcomes
17/09/2018
AACC 2018 abstracts

*NEW* Section 7.3. Sample redilution
*NEW* Figure 7.4. Proportion of samples giving a final result at each dilution on the Optilite analyser.
16/08/2018
Fotiou 2018 [1104]

Section 21.1. Introduction
Section 21.4. Guideline recommendations
16/08/2018
Caers 2018 [1108]

Section 21.1. Introduction
Section 21.2. Monoclonal proteins in solitary plasmacytoma
16/08/2018 Bernardi 2013 [1100]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Saez 2017 [1099]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Leurs 2017 [1097]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Bayart 2018 [1096]
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
16/08/2018 Tang 2018 [1095]
Section 12.2. Multiple myeloma and related malignant disorders
08/08/2018
AACC 2018 abstracts

Section 7.1.4. Sample and reagent stability
Section 7.4. Sample linearity
Section 7.5.3. Incidence of antigen excess
Section 7.6. Polymerisation
08/08/2018 Jülich 2018 [1089]
Section 35.4.2. Primary Sjögren’s syndrome
08/08/2018 James 2018 [1088]
Section 35.4.2. Primary Sjögren’s syndrome
08/08/2018 Sidiqi 2018 [1090]
Section 28.8. Prognostic value of sFLC response
26/07/2018 Wu 2018 [1084]
Section 14.2. Monoclonal sFLCs and SMM progression
26/07/2018 Lakshman 2018 [1083]
Section 14.2. Monoclonal sFLCs and SMM progression
20/06/2018
EHA abstracts

Section 8.7. Compliance with guidelines
Section 16.1 Introduction to nonsecretory multiple myeloma
Section 16.2. Diagnosis of nonsecretory multiple myeloma
Section 16.3. Monitoring nonsecretory multiple myeloma
Section 17.6. Immunoglobulin HLC immunoassays (Hevylite) at diagnosis
Section 20.3.2. Early sFLC response predicts outcome
Section 20.5. HLC analysis during response assessment
Section 24.8. Comparison of sFLCs and urinalysis for monitoring patients
Section 24.10. Organisational cost savings and other benefits of sFLC analysis
Section 28.5. Patients with low amyloidogenic FLCs have distinct clinical features
Section 28.6. Monitoring patients with AL amyloidosis
31/05/2018 Miyazaki 2018 [1068]
Section 18.4.3. HLC assays in MRD assessment
31/05/2018
Chae 2018 [1066]Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
Section 18.4.4. HLC assays improve detection of relapse
31/05/2018
Jacobs 2018 [1065]

Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
31/05/2018 Boyle 2016 [901]
Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
31/05/2018 Boyle 2015 [917]
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
31/05/2018
Katzmann 2015 [1064]Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
31/05/2018
Paolini 2015 [1062]

Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
Section 17.4. Limitations of electrophoresis
31/05/2018 Eckold 2010 [1067]
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
31/05/2018
Bradwell 2009 [127]Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
10/05/2018 Cancer Research UK Myeloma Survival Statistics 2018
[1054]
*NEW* Figure 12.3. Age-standardised five-year myeloma survival rates in England from 1971-2011
10/05/2018 Krok-Schoen 2018
[1055]
Section 12.2. Multiple myeloma and related malignant disorders
30/04/2018
Bosello 2018 [1051] *NEW* Section 35.4.4. Systemic sclerosis
30/04/2018
Lanteri 2014 [1050]*NEW* Section 35.4.4. Systemic sclerosis
30/04/2018
Steiner 2018 [1049]Section 26.4.1. Monoclonal gammopathy of renal significance
30/04/2018
Fernandez de Larrea 2018 [1048]Section 14.4. The prognostic value of changes in monoclonal protein concentration
30/04/2018
Bossuyt 2018
[1046]
Section 7.4. Antigen excess
Section 7.4.1. Incidence of antigen excess
Section 8.4.4. Antigen excess
30/04/2018
Sachchithanantham 2016 [1045]
Section 28.4. Prognostic value of sFLCs at diagnosis
25/04/2018
Kyle 2003 [355]Section 7.7. Biclonal gammopathies
Section 17.1. Intact immunoglobulin multiple myeloma: Introduction
25/04/2018
Campbell 2017 [1041]Section 7.7. Biclonal gammopathies
*NEW* Figure 7.7. sFLC concentrations at disease presentation in biclonal gammopathy MM patients.
Section 17.1. Intact immunoglobulin multiple myeloma: Introduction
Section 17.2. Free light chains at diagnosis
Section 19.2. Clonal populations in multiple myeloma
25/04/2018 Kyle 1981 [1042]Section 17.1. Intact immunoglobulin multiple myeloma: Introduction
25/04/2018
Lohr 2014 [1043]
Section 19.2. Clonal populations in multiple myeloma
23/04/2018
Kumar 2018 [1040]Section 25.8. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Multiple Myeloma V.4.2018
29/03/2018
Jimenez 2018 [1023]Section 13.2.2. Prognostic value of Hevylite in MGUS
28/03/2018
Premuzic 2018 [1034]Section 27.4.1. Plasma exchange
27/03/2018
Palladini 2018
[1032]
Section 28.4. Prognostic value of sFLCs at diagnosis
Section 28.5. Patients with low amyloidogenic FLCs have distinct clinical features
Section 28.8. Prognostic value of sFLC response
Section 28.8.1. sFLC response predicting cardiac outcomes
Section 28.8.2. sFLC response and renal outcome
27/03/2018
Dispenzieri 2018
[1033]
Section 28.8. Prognostic value of sFLC response
27/03/2018
Hajek 2017 [1029]Section 13.1. MGUS definition and frequency
Section 13.2. Risk factors for MGUS progression
Section 13.2.1. Prognostic value of serum FLCs in MGUS
Section 13.3.1. MGUS consistently precedes MM
23/03/2018
Landgren 2017 [1027]Section 13.1. MGUS definition and frequency
15/03/2018
Zeman 2018 [1026]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
15/03/2018
Gurtner 2018 [1025]Section 7.1.4. Sample and reagent stability
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
12/03/2018
Manwani 2018 [1024]Section 28.8. Prognostic value of sFLC response
28/02/2018
Correia 2017 [1018]Section 26.4.1. Monoclonal gammopathy of renal significance
28/02/2018
D'Souza 2016 [1019]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 20.5. HLC analysis during response assessment
28/02/2018
Suehara 2017 [1020]Section 20.5. HLC analysis during response assessment
28/02/2018
D'Auria 2017 [1021]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 20.5. HLC analysis during response assessment
25/01/2018
Kyle 2018 [1016]Section 13.3. MGUS as the precursor condition for MM and related disorders
25/01/2018
Kristinsson 2009 [1017]Section 13.3. MGUS as the precursor condition for MM and related disorders
24/01/2018
Palumbo 2015 [1012]
Section 20.1. Multiple Myeloma Prognosis: Introduction
16/01/2018
Thompson 2018[1011]
Section 3.6.1. Cerebrospinal fluid and free light chains: Introduction
12/01/2018
ASH Abstracts Section 28.7. Prognostic value of sFLC response
22/12/2017
Valencia-Vera 2017 [999]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
21/12/2017
Yagci 2015 [1007]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Tacchetti 2016 [1006]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Pratt 2015 [1005]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Gentili 2015 [1004]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Martinez-Lopez 2015 [1003]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Garcia 2016 [1002]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Fraser 2017 [1008]Section 35.2. Chronic Kidney Disease
Tandon 2017 [1000]Section 28.7. Prognostic value of sFLC response
Bossuyt 2017 [1001]Section 8.6.1. Comparison of absolute values
Section 8.7. Compliance with guidelines

Figures

References